welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

Eric Hoffman, PhD

Associate Dean for Research
School of Pharmacy and Pharmaceutical Sciences
Binghamton University
P.O. Box 6000
Binghamton, New York, United States

Dr. Hoffman has worked on Duchenne Muscular Dystrophy (DMD) since the late 1980’s, first working as a post-doctoral fellow with Louis Kunkel at Boston Children’s to identify the gene and protein (1986-1990), then running his own research group at University of Pittsburgh (1990-1998), then Children’s National Medical Center in Washington DC (1998-present).

He has led development of molecular diagnostics in muscular dystrophies, as well as efforts to understand the function of dystrophin in normal muscle, and the consequences of its absence in DMD. He co-founded ReveraGen in 2008 together with Drs. McCall and Nagaraju, and was appointed as CEO in 2014. Dr. Hoffman splits his time between his position as Associate Dean for Research in the School of Pharmacy and Pharmaceutical Sciences at Binghamton University and guiding ReveraGen as CEO.


Representative Publications:

Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study

Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle

Evidence for ACTN3 as a genetic modifier of Duchenne muscular dystrophy

Association Study of Exon Variants in the NF-κB and TGFβ Pathways Identifies CD40 as a Modifier of Duchenne Muscular Dystrophy